Thymosin Alpha-1 and KPV: Immune Peptide Research

Thymosin alpha-1 and KPV are both studied as immune-modulating peptides, but they approach the immune system from opposite directions. Thymosin alpha-1 is a 28-residue thymic peptide investigated mainly for its capacity to enhance T-cell and dendritic-cell responses. KPV is a tripeptide from the C-terminus of α-melanocyte-stimulating hormone, investigated mainly for its capacity to dampen inflammatory signalling. One has an approved drug form in several countries; the other remains a preclinical research compound.

Origin and discovery

Thymosin alpha-1

In the 1960s and 1970s, Allan Goldstein and Abraham White fractionated calf thymus extracts in search of factors that could restore immune function in thymus-deficient animals. The partially purified mixture, thymosin fraction 5, contained many peptides. Goldstein et al. (1977) isolated and sequenced one of them, thymosin alpha-1 (Tα1). It was later shown to be the N-terminal fragment of a larger, widely expressed protein, prothymosin alpha.

Synthetic Tα1 was developed under the international nonproprietary name thymalfasin and marketed as Zadaxin by SciClone Pharmaceuticals. It has been registered in a number of countries, particularly in Asia, Latin America and parts of Europe, for chronic hepatitis B and as an immune adjuvant.

KPV

α-Melanocyte-stimulating hormone (α-MSH) is a 13-residue peptide cleaved from pro-opiomelanocortin. Beyond its role in pigmentation, it has broad anti-inflammatory activity. James Lipton and colleagues found that the C-terminal tripeptide, Lys-Pro-Val (α-MSH 11–13), retained anti-inflammatory activity in animal models (Hiltz and Lipton, 1989). This made KPV an attractive minimal sequence for studying how α-MSH dampens inflammation.

Structure and chemistry

	Thymosin alpha-1	KPV
Sequence	Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN	Lys-Pro-Val
Length	28 residues, N-acetylated	3 residues
Approx. molecular weight	~3,108 Da	~342.4 Da
Parent molecule	Prothymosin alpha (N-terminus)	α-MSH (C-terminus, residues 11–13)
Character	Highly acidic, intrinsically disordered	Basic N-terminal lysine; compact

Tα1 carries many glutamate and aspartate residues, giving it a strong net negative charge and an unstructured conformation in water; it adopts helical structure in membrane-mimetic environments. KPV is small and polar. Native α-MSH is C-terminally amidated, and KPV is studied both as the free acid and as an amide, so certificates of analysis should state which form is supplied.

Mechanism studied

Thymosin alpha-1

Romani et al. (2004) reported that Tα1 activated dendritic cells through Toll-like receptor 9 (and TLR2 in some settings), engaging MyD88-dependent signalling. Downstream effects described across studies include:

• activation of NF-κB and p38 MAPK pathways in dendritic cells,
• increased production of IL-12 and type I interferons,
• promotion of T-helper type 1 differentiation and cytotoxic T-cell activity, and
• increased expression of MHC class I molecules on some cell types.

Tα1 has also been studied for effects on regulatory T cells and indoleamine 2,3-dioxygenase, which would suggest a balancing rather than purely stimulatory role.

KPV

KPV is taken up into intestinal epithelial and immune cells via the proton-coupled oligopeptide transporter PepT1, which is upregulated in inflamed colon (Dalmasso et al., 2008). Inside cells, KPV has been reported to inhibit NF-κB and MAPK activation and reduce production of IL-6, IL-8 and TNF-α. Unlike full-length α-MSH, KPV's activity does not appear to depend primarily on melanocortin receptor activation, although a contribution from MC1R has been proposed.

Research landscape by model system

In vitro

• Tα1: dendritic-cell maturation, T-cell proliferation and cytokine assays, and antiviral studies in cell lines.
• KPV: intestinal epithelial cell lines (Caco-2, HT29) stimulated with pro-inflammatory cytokines, keratinocytes and immune cell cultures.

Animal models

• Tα1: murine models of fungal infection (notably Aspergillus), viral infection, sepsis and tumour immunology.
• KPV: mouse colitis models induced by dextran sulfate sodium or trinitrobenzene sulfonic acid (Kannengiesser et al., 2008; Dalmasso et al., 2008), and studies using colon-targeted nanoparticle formulations (Laroui et al., 2010). Skin inflammation and wound models have also been examined.

Human trials

• Tα1: studied in clinical trials over several decades, including chronic hepatitis B and C, as a vaccine adjuvant, in oncology settings and in sepsis. Results have been heterogeneous. The ETASS trial in severe sepsis (Wu et al., 2013) reported encouraging findings, but a larger multicentre sepsis trial published in 2025 did not show a significant difference in mortality. Retrospective analyses during the COVID-19 pandemic produced conflicting results.
• KPV: no published clinical trials.

Evidence quality and open questions

For Tα1, evidence is moderate: a well-characterised molecule with defined immune pathways and many human studies, but with variable trial quality and inconsistent results across indications. Key questions include which patient populations, if any, show reproducible effects in rigorous trials, and how TLR-mediated activation reconciles with reported regulatory effects.

For KPV, evidence is low. Open questions include:

1. Mechanism. The intracellular target downstream of PepT1 uptake is not defined.
2. Replication. Colitis findings come from a limited number of groups.
3. Form and stability. Comparisons between free-acid and amidated KPV, and between free peptide and nanoparticle formulations, are incomplete.
4. Translation. No human pharmacokinetic or safety data have been published.

Regulatory and anti-doping status

Thymalfasin is approved in a number of countries outside the US and EU. It is not approved by the FDA or the EMA, although it has received FDA orphan drug designations for specific indications. KPV is not approved anywhere. Neither peptide is named on the WADA Prohibited List at the time of writing; researchers working with athletes should check the current list. Research-grade material of both is supplied for laboratory use only and is not equivalent to licensed pharmaceutical products.

Summary table

Attribute	Thymosin alpha-1	KPV
Origin	Thymosin fraction 5; N-terminus of prothymosin alpha	C-terminal tripeptide of α-MSH
Approx. molecular weight	~3,108 Da	~342.4 Da
Proposed mechanism	TLR9/TLR2 activation in dendritic cells; Th1 and cytotoxic T-cell support	PepT1 uptake; NF-κB and MAPK inhibition
Main model systems	Dendritic-cell assays; murine infection and tumour models	Epithelial cell lines; mouse colitis models
Human data	Multiple trials; registered drug (thymalfasin) in some countries	None published
Evidence level	Moderate	Low
FDA / EMA	Not approved	Not approved
WADA	Not named (check current list)	Not named (check current list)

References

• Goldstein AL, Low TL, McAdoo M, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725–729.
• Romani L, Bistoni F, Gaziano R, et al. Thymosin α1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232–4239.
• Camerini R, Garaci E. Historical review of thymosin α1 in infectious diseases. Expert Opin Biol Ther. 2015;15(Suppl 1):S117–S127.
• Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8.
• Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide α-MSH. FASEB J. 1989;3(11):2282–2284.
• Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of inflammatory diseases. Endocr Rev. 2008;29(5):581–602.
• Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324–331.
• Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.
• Laroui H, Dalmasso G, Nguyen HTT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843–853.